◎ Sugi Atlas

Atlas / Drug / Cisplatin

Cisplatin

drug
On this page

Also known as CIS-DDPCis-diamminedichloroplatinumCis-diamminedichloroplatinum iiCis-platinCis-platinum iiCisplatineCisplatinoCisplatinumFauldisciplaLiplacisNSC-119875Peyrone's saltPlatinolPlatinol-aqCis-diamminedichloroplatinum(ii)cis-Diamineplatinum (II) ComplexPlatinum-Triamine complexCis-PlatinumCisplatin(cis-Diammenedichloroplatinum)

Summary

Cisplatin (CHEMBL11359) is an approved small molecule (ATC L01XA01); indicated across 195 conditions including neoplasm and head and neck squamous cell carcinoma; with CIViC clinical evidence for 72 variant-indication associations (e.g. RRM1 Underexpression in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XA01
  • Indications: 195 conditions
  • Clinical trials: 2,943
  • Precision-oncology evidence (CIViC): 72 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL11359
NameCisplatin
TypeSmall molecule
Max phase4
ATCL01XA01

Also known as: CIS-DDP, Cis-diamminedichloroplatinum, Cis-diamminedichloroplatinum ii, Cis-platin, Cis-platinum ii, Cisplatin, Cisplatine, Cisplatino, Cisplatinum, Fauldiscipla, Liplacis, NSC-119875

Targets

Targets

Broader ChEMBL bioactivity targets: 22 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, ATP-dependent DNA helicase Q1, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Thromboxane-A synthase, Tyrosine-protein kinase Fyn, Epidermal growth factor receptor.

Bioactivity

ChEMBL activities: 22 potent at pChembl ≥ 5 of 34 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ALOX157Potency100nMCHEMBL_ACT_4463412
HSD17B106.9Potency125.9nMCHEMBL_ACT_4849419
TDP15.95Potency1122nMCHEMBL_ACT_3926891
HPGD5.65Potency2239nMCHEMBL_ACT_4787988
ADORA35.62Ki2398nMCHEMBL_ACT_7688629
ESR15.6IC502500nMCHEMBL_ACT_1461079
MAPT5.6Potency2512nMCHEMBL_ACT_4513521
EGFR5.58IC502621nMCHEMBL_ACT_7690831
MAPT5.55Potency2818nMCHEMBL_ACT_4036657
Q9F4F75.45Potency3548nMCHEMBL_ACT_4363344
P0DTD15.42IC503820nMCHEMBL_ACT_19964298
ADORA35.37IC504243nMCHEMBL_ACT_7688628
Q9F4F75.35Potency4467nMCHEMBL_ACT_4379604
MAPK35.33IC504624nMCHEMBL_ACT_7690823
FYN5.32IC504773nMCHEMBL_ACT_7690833
ESR15.24IC505800nMCHEMBL_ACT_1461080
MC5R5.22Ki6035nMCHEMBL_ACT_7690762
MC5R5.19IC506434nMCHEMBL_ACT_7690761
CCR25.15Ki7012nMCHEMBL_ACT_7688677
ESR15.1IC507900nMCHEMBL_ACT_1461076
TBXAS15.03IC509347nMCHEMBL_ACT_7690873
CXCR25.02Ki9461nMCHEMBL_ACT_7688685

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

195 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
carcinoma3MONDO:0004993EFO:0000313
squamous cell carcinoma3MONDO:0005096EFO:0000707
melanoma3MONDO:0005105EFO:0000756
cervical carcinoma3MONDO:0005131EFO:0001061
cervical adenocarcinoma3MONDO:0005153EFO:0001416
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
nasopharyngeal neoplasm3MONDO:0005375EFO:0004252
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
breast carcinoma3MONDO:0004989EFO:0000305
gastric carcinoma3MONDO:0004950EFO:0000178
urinary bladder neoplasm3MONDO:0004987EFO:0000294
gastric neoplasm3MONDO:0021085EFO:0003897
metastatic melanoma3MONDO:0005191EFO:0002617
carcinoma of esophagus3MONDO:0019086EFO:0002916
hepatocellular carcinoma3MONDO:0007256EFO:0000182
osteosarcoma3MONDO:0009807EFO:0000637
small cell lung carcinoma3MONDO:0008433EFO:0000702
sarcoma3MONDO:0005089EFO:0000691
breast neoplasm3MONDO:0021100EFO:0003869
mantle cell lymphoma3MONDO:0018876EFO:1001469
lung carcinoma3MONDO:0005138EFO:0001071
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
Hodgkins lymphoma3MONDO:0004952EFO:0000183
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
adenocarcinoma3MONDO:0004970EFO:0000228
cutaneous melanoma3MONDO:0005012EFO:0000389
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
gastric adenocarcinoma3MONDO:0005036EFO:0000503
germ cell tumor3MONDO:0005040EFO:0000514
lymphoma3MONDO:0005062EFO:0000574
mesothelioma3MONDO:0005065EFO:0000588
neuroblastoma3MONDO:0005072EFO:0000621
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
malaria3MONDO:0005136EFO:0001068
ovarian carcinoma3MONDO:0005140EFO:0001075
plasma cell myeloma3MONDO:0009693EFO:0001378
exocrine pancreatic carcinoma3MONDO:0005192EFO:0002618
thymus neoplasm3MONDO:0005197EFO:0002626
medulloblastoma3MONDO:0007959EFO:0002939
laryngeal neoplasm3MONDO:0021071EFO:0003817
tumor of uterus3MONDO:0021353EFO:0003859
oral cavity neoplasm3MONDO:0021245EFO:0003868
biliary tract neoplasm3MONDO:0005304EFO:0003891
ovarian neoplasm3MONDO:0021068EFO:0003893
colorectal neoplasm3MONDO:0005335EFO:0004142
testicular cancer3MONDO:0005447EFO:0004281
gallbladder neoplasm3MONDO:0021253EFO:0004606
cholangiocarcinoma3MONDO:0019087EFO:0005221
primitive neuroectodermal tumor3MONDO:0005462EFO:0005235
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
head and neck cancer3MONDO:0005627EFO:0006859
hepatoblastoma3MONDO:0018666EFO:1000292
inflammatory breast carcinoma3MONDO:0006804EFO:1000984
oropharynx cancer3MONDO:0004608EFO:1001931
gallbladder carcinoma3MONDO:0003220EFO:1001956
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
soft tissue sarcoma3MONDO:0018078EFO:1001968
lung adenocarcinoma3MONDO:0005061EFO:0000571
brain neoplasm3MONDO:0021211EFO:0003833
pharynx cancer3MONDO:0005517EFO:0005577
undifferentiated carcinoma3MONDO:0005617EFO:0006772
urothelial carcinoma3MONDO:0040679EFO:0008528
fallopian tube carcinoma3MONDO:0006206EFO:1000251
adrenal cortex carcinoma3MONDO:0006639EFO:1000796
peritoneal neoplasm3MONDO:0006901EFO:1001100
stomatitis3MONDO:0004842EFO:1001904
ganglioneuroblastoma3MONDO:0005035EFO:0000502
hypopharyngeal carcinoma3MONDO:0005216EFO:0002938
anemia3MONDO:0002280EFO:0004272
mediastinal cancer3MONDO:0005843EFO:0007362
central nervous system neoplasm3MONDO:0006130EFO:1000158
ovarian embryonal carcinoma3MONDO:0003581EFO:1000415
ovarian yolk sac tumor3MONDO:0006344EFO:1000437
choriocarcinoma of testis3MONDO:0003508EFO:1000564
testicular yolk sac tumor3MONDO:0003402EFO:1000574
mucositis3MONDO:0020579EFO:1001898
vulva cancer3MONDO:0001528MONDO:0001528
brain cancer3MONDO:0001657MONDO:0001657
anus neoplasm3MONDO:0003046MONDO:0001879
fallopian tube neoplasm3MONDO:0021092MONDO:0002158
teratoma3MONDO:0002601MONDO:0002601
uterine cancer3MONDO:0002715MONDO:0002715
seminoma3MONDO:0003001MONDO:0003001
ependymoma3MONDO:0016698MONDO:0003478
ovarian cancer3MONDO:0008170MONDO:0008170
lung neoplasm3MONDO:0021117MONDO:0008903
endometrium neoplasm3MONDO:0021251MONDO:0011962
oral cavity squamous cell carcinoma3MONDO:0004958EFO:0000199
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
paranasal sinus neoplasm3MONDO:0005289EFO:0003866
oral cavity cancer3MONDO:0005515EFO:0005570
head and neck neoplasm3MONDO:0005586EFO:0005950
laryngeal squamous cell carcinoma3MONDO:0005595EFO:0006352
hypopharynx squamous cell carcinoma3MONDO:0044638EFO:1001960
skin neoplasm3MONDO:0002531MONDO:0002898
pancreatic neoplasm3MONDO:0021040EFO:0003860
retinoblastoma3MONDO:0008380MONDO:0008380
uterine corpus cancer3MONDO:0006003EFO:0007532
malignant pancreatic neoplasm3MONDO:0009831EFO:1000359
malignant peritoneal mesothelioma3MONDO:0005512EFO:0005567
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
follicular lymphoma3MONDO:0018906MONDO:0018906
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
leukemia2MONDO:0005059EFO:0000565
renal cell carcinoma2MONDO:0005086EFO:0000681
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
salivary gland cancer2MONDO:0004669EFO:0003826
thymoma2MONDO:0006456EFO:1000581
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
myelodysplastic syndrome2MONDO:0018881EFO:0000198
carcinoid tumor2MONDO:0005369EFO:0004243
thymic carcinoma2MONDO:0006451EFO:1000576
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
penile neoplasm2MONDO:0006895MONDO:0001325
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
kidney cancer2MONDO:0002367MONDO:0002367
nasal cavity and paranasal sinus lethal midline granuloma2MONDO:0006828MONDO:0019472
glioma2MONDO:0021042MONDO:0100342
differentiated thyroid carcinoma2MONDO:0015447EFO:1002017
lung large cell carcinoma2MONDO:0003050EFO:0003050
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
glioblastoma2MONDO:0018177EFO:0000519
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
verrucous carcinoma2MONDO:0006006EFO:0007535
malignant mesothelioma2MONDO:0006292EFO:1000355
ocular melanoma2MONDO:0006325EFO:1000403
olfactory neuroblastoma2MONDO:0006329EFO:1000407
paraganglioma2MONDO:0000448EFO:1000453
uveal melanoma2MONDO:0006486EFO:1000616
bile duct neoplasm2MONDO:0021662MONDO:0003059
tongue cancer2MONDO:0004631MONDO:0004631
pancreatic ductal adenocarcinoma2MONDO:0005184MONDO:0005184
liver disorder1MONDO:0005154EFO:0001421
endometrioid adenocarcinoma1MONDO:0005026EFO:0000466
basal cell carcinoma1MONDO:0020804EFO:0004193
kidney disorder1MONDO:0005240EFO:0003086
ovarian serous cystadenocarcinoma1MONDO:0006046EFO:1000043
hilar cholangiocarcinoma1MONDO:0003345EFO:1001959
digestive system neoplasm1MONDO:0021223EFO:0008549
female reproductive system neoplasm1MONDO:0021148MONDO:0021148
primary myelofibrosis1MONDO:0009692MONDO:0044903
neuroendocrine neoplasm1MONDO:0019496EFO:1001901
cystic, mucinous, and serous neoplasm1MONDO:0006720MONDO:0037256
rhabdomyosarcoma0MONDO:0005212EFO:0002918

46 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,943.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,943 total).

PhaseTrials
PHASE3697
PHASE2691
PHASE1/PHASE2104
PHASE2/PHASE382
PHASE426

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05689671PHASE4ACTIVE_NOT_RECRUITINGPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT06388135PHASE4NOT_YET_RECRUITINGSerplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT06457503PHASE4RECRUITINGA Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06879691PHASE4ACTIVE_NOT_RECRUITINGA Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
NCT00046969PHASE4COMPLETEDEpoetin Beta in Treating Anemia in Patients With Cervical Cancer
NCT00226473PHASE4UNKNOWNStandard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
NCT00772681PHASE4COMPLETEDEfficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
NCT01424839PHASE4UNKNOWNProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
NCT01501136PHASE4UNKNOWNTreatment of Natural Killer/T Cell Lymphoma-I/II
NCT02088515PHASE4COMPLETEDNedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
NCT02348450PHASE4UNKNOWNIrinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer
NCT02484677PHASE4COMPLETEDPharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy
NCT02497118PHASE4COMPLETEDRecombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
NCT02513342PHASE4UNKNOWNEndostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
NCT02513355PHASE4UNKNOWNEndostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
NCT02858804PHASE4COMPLETEDEDOCH Alternating With DHAP for New Diagnosed Younger MCL
NCT02996214PHASE4UNKNOWNPaclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)
NCT03069820PHASE4UNKNOWNClarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
NCT03071822PHASE4UNKNOWNCombination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
NCT03092986PHASE4COMPLETEDOutcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03413436PHASE4COMPLETEDLobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
NCT03998696PHASE4COMPLETEDAn Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.
NCT04999878PHASE4UNKNOWNA Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
NCT05312840PHASE4UNKNOWNEfficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer
NCT05603065PHASE4UNKNOWNTislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)
NCT05730777PHASE4UNKNOWNCorrelation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
NCT00392327PHASE3ACTIVE_NOT_RECRUITINGChemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00470223PHASE3ACTIVE_NOT_RECRUITINGCombined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
NCT00572169PHASE3ACTIVE_NOT_RECRUITINGUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
NCT00588770PHASE3ACTIVE_NOT_RECRUITINGChemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00980460PHASE3ACTIVE_NOT_RECRUITINGRisk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
NCT01566240PHASE3ACTIVE_NOT_RECRUITINGInduction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT01704716PHASE3RECRUITINGHigh Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01810913PHASE2/PHASE3RECRUITINGTesting Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
NCT01924819PHASE2/PHASE3ACTIVE_NOT_RECRUITINGTrial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
NCT02135042PHASE2/PHASE3ACTIVE_NOT_RECRUITINGIndividualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NCT02170090PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
NCT02215265PHASE3ACTIVE_NOT_RECRUITINGPost-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02221999PHASE2/PHASE3ACTIVE_NOT_RECRUITINGWeekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
NCT02265770PHASE2/PHASE3RECRUITINGAn International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

Clinical evidence (CIViC)

Variant × indication × effect (72 predictive associations from 75 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabine + CisplatinCIViC BEID2905 +1
ABCB1 I1145ILung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + CarboplatinCIViC BEID675
AURKA EXPRESSIONEsophagus Squamous Cell CarcinomaSensitivity/ResponseRadiation Therapy + Fluorouracil + CisplatinCIViC BEID1653
BRCA1 MutationTriple-receptor Negative Breast CancerSensitivity/ResponseCisplatin + CarboplatinCIViC BEID1684
BRCA1 MutationPancreatic CancerSensitivity/ResponseCisplatin + OxaliplatinCIViC BEID5915
BRCA1 MutationPancreatic CancerSensitivity/ResponseCisplatin + Gemcitabine + VeliparibCIViC BEID5932
BRCA2 MutationTriple-receptor Negative Breast CancerSensitivity/ResponseCarboplatin + CisplatinCIViC BEID1685
BRCA2 MutationPancreatic CancerSensitivity/ResponseCisplatin + Gemcitabine + VeliparibCIViC BEID5933
CDKN1B EXPRESSIONHead And Neck Squamous Cell CarcinomaSensitivity/ResponseCisplatin + FluorouracilCIViC BEID889
ERCC1 ExpressionBladder CarcinomaSensitivity/ResponseCisplatinCIViC BEID809
ERCC1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + GemcitabineCIViC BEID6431
ERCC1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatinCIViC BEID6433
ETS2 RS461155Lung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + CisplatinCIViC BEID1060
FGFR3 MutationUrinary Bladder CancerSensitivity/ResponseCisplatin + GemcitabineCIViC BEID7566
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + Gemcitabine + CisplatinCIViC BEID12044
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + GemcitabineCIViC BEID6436
SMARCA4 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + VinorelbineCIViC BEID837
TP53 OverexpressionStomach CancerSensitivity/ResponseCisplatin + Mitomycin + EtoposideCIViC BEID2799
XRCC1 Q399RCervical CancerSensitivity/ResponseCisplatin + CarboplatinCIViC BEID673
MIR21 OverexpressionLung Non-small Cell CarcinomaResistanceCisplatinCIViC BEID8109 +1
AURKA OverexpressionLung Non-small Cell CarcinomaResistanceCisplatinCIViC BEID871
CD44 CD44v6Cervical CancerResistanceCisplatinCIViC BEID9481
DNMT1 EXPRESSIONGastric AdenocarcinomaResistanceCisplatinCIViC BEID946
ERCC2 K751QOsteosarcomaResistanceCisplatinCIViC BEID676
GNAS c.393T>CEsophageal CancerResistanceCisplatin + FluorouracilCIViC BEID2895
KRAS RS61764370Head And Neck Squamous Cell CarcinomaResistanceCisplatinCIViC BEID872
MDM2 EXPRESSIONMalignant Pleural MesotheliomaResistancePemetrexed + CisplatinCIViC BEID827
TP53 ALTERATIONOvarian CancerResistanceCarboplatin + CisplatinCIViC BEID2771
TP53 OverexpressionOvarian CancerResistanceCarboplatin + CisplatinCIViC BEID3013
ERCC1 ExpressionBladder CarcinomaPaclitaxel + Cisplatin + GemcitabineCIViC BEID6438

+42 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot